Leaders

Dr Bertrand Collin obtained his diploma in radiopharmacy and his PhD in pharmacology in 2006.

A hospital radiopharmacist since graduating, he is one of the designers of the IMATHERa team (Nuclear Medicine Department of the Georges-François Leclerc Centre, Dijon, Prof. Alexandre Cochet), which he has headed since 2010.

His research focuses on the design and evaluation of theranostic agents and strategies for precision medicine applied to oncology.

He is also an associate professor in medicinal chemistry, radiopharmacy and molecular imaging at the Faculty of Pharmacy in Dijon, where he is co-director of the international master’s degree in ‘Innovative Drugs: pharmaco-imaging, nanovectorisation and theranostics’ and the industry-research pharmacy course In terms of research, Dr Bertrand Collin is attached to the Institut de Chimie Moléculaire de l’Université de Bourgogne – ICMUB – UMR CNRS 6302 (Pr Franck Denat).

Since the team’s inception, Dr Bertrand Collin has been involved in a number of public-private partnerships that have enabled the implementation of a mixed research and services model. As a result of this structuring, the Dijon pharmaco-imaging consortium, of which the CGFL and ICMUB are members, has been able to put together and obtain a number of structuring calls for projects.

Dr Alexandra Oudot, obtained her PhD in Cardiovascular Pharmacology from the University of Burgundy in 2004.

Her PhD work dealt with the role of cardiac oxidative stress and renin-angiotensin system in myocardial ischemia and aging. She also worked in the Cardiology Department of Dijon CHU in 2004/2005 as a clinical research associate before joining Pelvipharm (Orsay, France), a CRO specialized in the preclinical evaluation of new therapeutic substances, where she worked as a project manager and carried out about 60 studies for worldwide-based pharmaceutical industries. Besides these fee-for-service activities, she was in charge of the animal housing unit and participated in the development and characterization of new animal models of cardiovascular diseases (hypertension, atherosclerosis, metabolic syndrome…).

She joined IMATHERa in 2011 as a project manager in charge of setting up the fee for services activity and developing the in vivo imaging capabilities. She participated in the setting up of the cardiac imaging activity in rodents and developed in-house models of cardiac diseases (Onco-cardiology and interstitial fibrosis models). In parallel, since 2012, Dr Oudot is in charge of operational management of the IMAPPI Project (Integrated Magnetic resonance And Positron emission tomography in Preclinical Imaging – ANR- 10-EQPX-05-01) : This project, funded by the french national research agency (7.3 M€) allowed to install one the first prototype of integrated PET-MRI preclinical system in Europe which results today in a fully-operational integrated system for which PET and MRI image are acquired simultaneously.

Today, Dr Oudot is chief operating officer of the team. She supervises the overall operational running of the team, coordinates the various studies (services and R&D) conducted, and manages research and fee-for services projects (oncology, cardiovascular studies).